Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|6|1697-1709

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.6, 2015-12, pp. : 1697-1709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 243-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon‐γ or interleukin‐10 are expanded in asymptomatic, E antigen‐negative patients with persistent hepatitis B virus infection

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 335-345

John Wiley & Sons Inc

Access to resources Recommend Favorite

Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

By  

Oncology, Vol. 90, Iss. 4, 2016-03 ,pp. : 199-208

Karger

Access to resources Recommend Favorite

P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction?

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 50-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite